SEC Form 4 · accession 0001193125-26-301996
Amylyx Pharmaceuticals, Inc. · AMLX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gina Mazzariello
Officer — Chief Legal Officer
Period of report
Jul 9, 2026
Accepted (ET)
Jul 13, 2026 · 4:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001658551
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 9, 2026 | S | 15,000 | $18.3164 | D | 194,090 | D | |
| Common StockF3 | Jul 10, 2026 | S | 15,000 | $17.6081 | D | 179,090 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 9, 2026.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.92 to $18.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.15 to $18.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.